Do you want to read an article? Please log in or register.
LBA109: ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1–positive metastatic TNBC
Breast Cancer
CHICAGO 2025
Related content
ESMO 2025
Breast Cancer
ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab maintains QoL and delays functional decline in patients with PD-L1-positive metastatic TNBC
ESMO 2025
Breast Cancer
ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors
SABCS 2025
Breast Cancer
ASCENT-03: Frontline sacituzumab govitecan improves QoL versus chemotherapy in patients with metastatic TNBC ineligible for PD-1/PD-L1 inhibitors
RECOMMENDED
Breast Cancer
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
★ 3
Recommended by
Dr Andreas Müller, Faculty Member
N Engl J Med
Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, Rapoport B, Im SA, Pistilli B, Mchayleh W, Cescon DW, Watanabe J, Bañuelas MAL, Freitas-Junior R, Salvador Bofill J, Afshari M, Gary D, Wang L, Lai C, Schmid P, ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators
doi: 10.1056/NEJMoa2508959
SABCS 2025
Breast Cancer
DESTINY-Breast09: Favorable PROs with T-DXd plus pertuzumab in first-line HER2-positive advanced and metastatic breast cancer
CHICAGO 2025
Gastrointestinal Cancer
LBA4002: DESTINY-Gastric04: Improved OS with second-line T-Dxd versus ramucirumab plus paclitaxel in patients with HER2-positive metastatic GC/GEJA
SPECIAL REPORT
Gynecologic Cancer
Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer
Lung, Respiratory and Thoracic Cancer
Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis
Lung Cancer
Tang Y, Du W, Zhang X, Yang X, Zhou Y, Fu S, Zhang L, Hong S
doi: 10.1016/j.lungcan.2025.108855
ELCC 2025
Lung, Respiratory and Thoracic Cancer